Parasternal block and chronic pain in patients undergoing cardiac surgery

Parasternal block and chronic postoperative pain in patients undergoing cardiac surgery: Prospective, randomized and controlled clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-9hdqfcp

Enrollment

Registered

2026-03-31

Start date

2024-01-30

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain Thoracic Surgery

Interventions

This is a two-arm randomized controlled clinical trial that will include a total of 60 participants, randomly allocated in a 1:1 ratio into two groups, with 30 participants assigned to the experimenta

no masking (blinding) will be applied, characterizing the study as open-label, as both the healthcare professionals performing the intervention and the participants will be aware of group allocation d

participants in the experimental group will undergo an ultrasound-guided bilateral parasternal block performed at the T3–T4 intercostal level using a 20-gauge needle, with administration of 20 millili

participants in the control group will receive only the same multimodal analgesia protocol without the parasternal block

all participants will undergo standardized anesthetic induction and maintenance according to institutional protocol, including administration of midazolam, ketamine, etomidate, fentanyl, remifentanil,

Eligibility

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients of both sexes who will undergo cardiac surgery; age between 18 and 80 years

Exclusion criteria

Exclusion criteria: Patients with puncture site infection; patients with systemic infection or hemodynamic instability

Design outcomes

Primary

Measure	Time frame
To assess the incidence and intensity of chronic postoperative pain in patients undergoing cardiac surgery, by applying the Numerical Verbal Pain Scale at standardized times (immediately after extubation, at 2 hours, 12 hours and 24 hours) and by telephone contact after 12 weeks, when the Douleur Neuropathique en 4 Questions questionnaire will also be applied to assess neuropathic pain.	—

Secondary

Measure	Time frame
Secondary outcomes include the assessment of intraoperative hemodynamic parameters, immediate postoperative pain intensity, opioid consumption in the first 24 hours, and the presence of neuropathic pain after 12 weeks; outcome verification will be performed using the Numerical Verbal Pain Scale at standardized times (immediately after extubation, at 2 hours, 12 hours, and 24 hours) and by telephone contact after 12 weeks, when the Douleur Neuropathique en 4 Questions questionnaire will also be applied to assess neuropathic pain; additionally, hemodynamic parameters such as systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate will be monitored during the intraoperative period, as well as opioid consumption during the intra- and postoperative periods, including the need for rescue doses, allowing for quantitative and comparative analysis between the groups.	—

Measure

Time frame

Secondary outcomes include the assessment of intraoperative hemodynamic parameters, immediate postoperative pain intensity, opioid consumption in the first 24 hours, and the presence of neuropathic pain after 12 weeks; outcome verification will be performed using the Numerical Verbal Pain Scale at standardized times (immediately after extubation, at 2 hours, 12 hours, and 24 hours) and by telephone contact after 12 weeks, when the Douleur Neuropathique en 4 Questions questionnaire will also be applied to assess neuropathic pain; additionally, hemodynamic parameters such as systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate will be monitored during the intraoperative period, as well as opioid consumption during the intra- and postoperative periods, including the need for rescue doses, allowing for quantitative and comparative analysis between the groups.

—

Countries

Contacts

Public ContactRodrigo Miranda

Faculdade de Medicina da Universidade de São Paulo

drrodrigovital@gmail.com+55-83-998451216

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: May 1, 2026